Drug intelligence / Profile preview

nicofuranose

Development stage
Discontinued
Lead developer
Norgine
Modality
Small Molecules
Administration
Oral
01

Overview

Nicofuranose is a nicotinic acid derivative that serves as a prodrug of niacin (nicotinic acid). Chemically, it is the tetranicotinic acid ester of fructose, specifically 1,3,4,6-tetranicotinoyl-fructofuranose. It was historically used as an antihyperlipidemic agent and a peripheral vasodilator. By slowly releasing nicotinic acid into the bloodstream upon hydrolysis, nicofuranose helps to mitigate the intense cutaneous flushing often associated with immediate-release nicotinic acid formulations. Its therapeutic applications included the treatment of hyperlipidemia and various peripheral vascular disorders, such as Raynaud's disease and arteriosclerosis obliterans, by improving blood circulation and lowering serum cholesterol and triglyceride levels.

Brand names
Bradilan
Other names
1,3,4,6-tetranicotinoyl-fructofuranosetetranicotinoylfructosefructose tetranicotinate
02

Targets

DGAT2 (Hepatic diacylglycerol acyltransferase 2)HCAR2 (Hydroxycarboxylic acid receptor 2)

Beyond the preview

Go deeper on nicofuranose.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nicofuranose.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call